Menten AI

Menten AI is a private, preclinical-stage biotech leveraging a proprietary generative AI platform, MAUD 1.0, to design and optimize peptide macrocycles. Founded in 2020, the company has validated its platform, reporting high hit rates and the achievement of key drug-like properties such as nM potency and oral bioavailability. Backed by leading venture capital firms and with a partnership with Bristol Myers Squibb, Menten AI operates as a platform company, aiming to expand the druggable genome and accelerate the development of next-generation peptide therapeutics.

MAUD 1.0 (Multi-parametric AI for Unbiased Design): A generative AI platform that integrates physics-based modeling and quantum chemistry simulations to design novel, drug-like peptide macrocycles de novo, optimizing for multiple properties like potency, permeability, and oral bioavailability simultaneously.

Menten AI competes in the crowded AI-driven drug discovery space against companies like Recursion, Exscientia, and Insilico Medicine, and more specifically in computational peptide design against firms such as Peptone and Nivien Therapeutics. Its differentiation lies in its physics-informed generative AI approach and focus on peptide macrocycles with drug-like properties.